REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regio...(indings presented by investigators in ea...),Health

Date:2/4/2008

indings presented by investigators, in each of the three psoriasis clinical trials evaluated, the Study of Psoriasis with Infliximab [REMICADE] Induction Therapy (SPIRIT), the European Infliximab for Psoriasis [REMICADE] Efficacy and Safety Study (EXPRESS), and the Evaluation of Infliximab for Psoriasis in a [REMICADE] Efficacy and Safety Study (EXPRESS II), a substantial proportion of REMICADE-treated patients experienced dramatic improvements in head- and neck-related psoriasis, trunk psoriasis and psoriasis of the lower and upper extremities as compared with the placebo group. Additionally, the improvements in each body region were generally consistent with the overall PASI response. At week 10, the proportions of patients achieving at least a 75 percent improvement or at least a 90 percent improvement of head- and neck-related psoriasis in the combined REMICADE groups (3 mg/kg and 5 mg/kg) versus placebo were as follows: SPIRIT, 86 percent versus 22 percent achieved at least 75 percent improvement and 69 percent versus 12 percent achieved at least 90 percent improvement; EXPRESS, 85 percent versus 13 percent achieved at least 75 percent improvement and 73 percent versus 8 percent achieved at least 90 percent improvement; EXPRESS II, 79 percent versus 10 percent achieved at least 75 percent improvement and 67 percent versus 6 percent achieved at least 90 percent improvement.

PASI responses for trunk psoriasis in the combined REMICADE groups (3 mg/kg and 5 mg/kg) versus placebo were as follows: SPIRIT, 86 percent versus 12 percent achieved at least 75 percent improvement and 66 percent versus 4 percent achieved at least 90 percent improvement; EXPRESS, 87 percent versus 5 percent achieved at least 75 percent improvement and 72 percent versus 1 percent achieved at least 90 percent improvement; EXPRESS II, 79 percent versus 7 percent achieved at least 75 percent improvement and 59 percent versus 4 percent achieved at least 90 percent improvement.

Patie
'/>"/>

SOURCE Centocor, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients